HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population - Full Text View

HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population

This study has been completed.

Sponsors and Collaborators:	Asociación para Evitar la Ceguera en México Instituto Nacional de Referencia Epidemiológica (INdRE)
Information provided by:	Asociación para Evitar la Ceguera en México
ClinicalTrials.gov Identifier:	NCT00600236

Purpose

One of the first causes of irreversible blindness in mexican population is diabetic retinopathy which is clearly diferent between patients the time of evolution and development of retinopathy and complications. The aim of this study is to explore the inmunogenetic profile and the influence of HLA in this variations of the sickness to predict the severity of diabetic complications.

Condition	Intervention	Phase
Diabetes Mellitus Type 2 Proliferative Diabetic Retinopathy	Procedure: blood sample	Phase III

MedlinePlus related topics:

Diabetes Diabetic Eye Problems Retinal Disorders

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Prevention, Non-Randomized, Single Blind, Active Control, Parallel Assignment, Efficacy Study

Official Title:	HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population

Further study details as provided by Asociación para Evitar la Ceguera en México:

Estimated Enrollment:	300
Study Start Date:	September 2004
Study Completion Date:	January 2008
Primary Completion Date:	January 2008 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Diabetes mellitus type 2 with 10 years of diagnosis and no diabetic retinopathy
Diabetes mellitus type 2 with 10 years of diagnosis and proliferative retinopathy

Exclusion Criteria:

Systemic hipertension
Cardic disease
Lupus
Any kind of artritis
Allergies
Optic Neuritis
VKH
Cancer
Inmunological diseases

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00600236

Locations


Mexico, Mexico DF
	Asociación para Evitar la Ceguera en México, Hospital "Luis Sanchez Bulnes"
	Mexico City, Mexico DF, Mexico, 04030

Sponsors and Collaborators

Asociación para Evitar la Ceguera en México

Instituto Nacional de Referencia Epidemiológica (INdRE)

Investigators


Principal Investigator:	Hugo Quiroz-Mercado, MD	Asociación para Evitar la Ceguera en México, Hospital "Luis Sánchez Bulnes"

More Information

Study ID Numbers:	APEC-0018
First Received:	June 30, 2006
Last Updated:	January 23, 2008
ClinicalTrials.gov Identifier:	NCT00600236
Health Authority:	Mexico: Secretaria de Salud

Keywords provided by Asociación para Evitar la Ceguera en México:

Diabetes mellitus type 2 with 10 years of diagnosis and no diabetic retinopathy

Diabetes mellitus type 2 with 10 years of diagnosis and proliferative diabetic retinopathy

Study placed in the following topic categories:

Metabolic Diseases

Eye Diseases

Diabetes Mellitus

Vascular Diseases

Endocrine System Diseases

Diabetic Angiopathies

Diabetic Retinopathy

Diabetes Mellitus, Type 2

Endocrinopathy

Glucose Metabolism Disorders

Metabolic disorder

Retinal Diseases

Diabetes Complications

Additional relevant MeSH terms:

Cardiovascular Diseases

ClinicalTrials.gov processed this record on October 28, 2008